Learning Objectives

  • Demonstrate an increase in your knowledge of clinical medicine.
  • Evaluate the appropriateness of clinical information as it applies to the care of your patients.
  • Demonstrate an improvement in your ability to make decisions that provide safe and effective medical care.
  • Recognize areas of personal strength and areas for growth in clinical knowledge.

Intended Audience

Physicians and residents who are seeking to maintain and augment their knowledge in pediatric medicine and/or who are preparing for their initial board certification or recertification.

Accreditation

The Massachusetts Medical Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Massachusetts Medical Society designates this enduring material for a maximum of 151 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ABP MOC StatementABP MOC points

Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 150 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Royal College of Physicians and Surgeons of Canada

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Method of Participation

You must answer questions correctly to receive AMA PRA Category 1 Credits™ and ABP MOC points toward Certification Maintenance.

Six questions answered correctly are designated for 1 AMA PRA Category 1 Credit™ and 1 ABP MOC point.

CME Accreditation Term

Original Release Date: February 1, 2017
Review Date: 2018, 2019
Termination Date: February 1, 2023

The Massachusetts Medical Society (MMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and must ensure independence, balance, and scientific rigor in its accredited continuing education activities. All individuals in control of the content for an MMS accredited continuing education activity must disclose all financial relationships with ineligible companies.

Individual Disclosures

Below are all relevant financial relationships reported by NEJM Knowledge+ contributors during the past 3 years.

Vaneeta Bamba, MD

2020 Nothing disclosed
2021 Novo Nordisk, Growth Advisory Board for Genetic Short Stature, discontinued Nov 2020
2022 Nothing disclosed

Ethan Brown, MD

2020

Gateway Institute for Brain Research, grant/contract research

Rune Labs, consultant, discontinued Apr 2019

2021Rune Labs, consultant, discontinued Apr 2019
2022Rune Labs, consultant

Ezra M. Cohen, MD

2020Nothing disclosed
2021Cornerstone Research Group, consultant
2022Nothing disclosed

Nathan Connell, MD

2020Nothing disclosed
2021Nothing disclosed
2022Takeda Pharmaceutical, consultant

Rajesh T. Gandhi, MD

2020Merck, scientific advisory board
2021Merck, scientific advisory board
2022Nothing disclosed

Jonathan S. Hausmann, MD

2020Novartis, consultant and advisory board member
2021

Pfizer, consultant, discontinued Dec 2020

Biogen, consultant, discontinued Dec 2020

Novartis, consultant

2022

Pfizer, consultant, discontinued Dec 2020

Biogen, consultant, discontinued Dec 2020

Novartis, consultant

Brian C. Healy, MD

2020

Analysis Group, grant funding

Celgene, grant funding

Novartis, grant funding

Merck Serono, grant funding

Verily Life Sciences, grant funding

Tiziana, grant funding

Genzyme, grant funding

2021

Analysis Group, grant support

Celgene (Bristol–Myers Squibb), grant support

Verily, grant support

Novartis, grant support

Merck Serono, grant support

Genzyme, grant support

2022

Analysis Group, research support to institution, discontinued Nov 2020

Celgene (Bristol–Myers Squibb), research support to institution, discontinued Nov 2020

Novartis, research support

Mihir M. Kamdar, MD

2020

Amorsa Therapeutics, scientific advisory board

Medtronic, consultant

2021

Amorsa Therapeutics, scientific advisory board, stockholder

Medtronic, consultant, fees

Fern Health, consultant, fees

2022Nothing disclosed

Ruslan Korets, MD

2020Nothing disclosed
2021Boston Scientific, consultant
2022Boston Scientific, consultant

Jenna C. Lester, MD

2020 Rodan + Fields, consultant

Leigh C. Reardon, MD

2020Nothing disclosed
2021

Janssen, speaker

CareDx, participant in advisory board discussion, discontinued Dec 2020

2022Janssen, advisory committee

Derrick J. Todd, MD, PhD

2020Optum, consultant

Ruth Ann Vleugels, MD, MPH, MBA

2021Pfizer, principal investigator for a clinical trial

Raymond Y. Wang, MD

2020

Biomarin Pharmaceuticals, advisory board / consultation, equity ownership

RegenxBio, advisory board / consultation, equity ownership

Takeda Pharmaceutical, advisory board / consultation

Orphazyme, advisory board / consultation

Inventiva Pharmaceutical, advisory board / consultation

Sarepta Therapeutics, equity ownership

2021

Biomarin Pharmaceutical, speaking engagement, discontinued Jul 2019

Biomarin Pharmaceutical, advisory committee, discontinued Sep 2019

RegenxBio, advisory committee, discontinued May 2020

Takeda Pharmaceutical, advisory committee, discontinued Aug 2020

Ultragenyx Pharmaceutical, webinar, discontinued Nov 2020

Inventiva Pharmaceutical, advisory committee, discontinued Dec 2020

Neurogene, advisory committee, discontinued Nov 2020

Denali Therapeutics, drug monitoring committee

2022

Biomarin, ad hoc advisory board, discontinued Oct 2021

Orphazyme, ad hoc FDA advisory meeting, discontinued Oct 2021

Sio Gene Therapies, consultant, discontinued Nov 2021

Sio Gene Therapies, ad hoc advisory board, discontinued Aug 2021

Inventiva Pharmaceutical, ad hoc advisory board, discontinued Jul 2021

Takeda Pharmaceutical, ad hoc advisory board, discontinued Mar 2021

Ultragenyx, speaker, discontinued Nov 2020

Neurogene, ad hoc advisory board, discontinued Oct 2020

Regenxbio, ad hoc advisory board, discontinued Apr 2020

Sharmeel K. Wasan, MD

2020Nothing disclosed
2021Pfizer, grant support
2022Nothing disclosed

All relevant financial relationships have been mitigated prior to the beginning of this activity in accordance with ACCME and MMS policies. All other individuals in control of the content have reported no relevant financial relationships with ineligible companies for this activity. The complete list of contributors can be found here.

Disclosure of Commercial Support

No commercial support was received for this activity.

Medium or Combination of Media Used

This is an adaptive self-assessment tool designed to adjust to the learner’s strengths and areas for growth, and can be accessed from a desktop, laptop, tablet, or smartphone. Learners choose the subspecialty area and are presented with a sequence of questions. After each question is answered, the user is provided with the key learning point, detailed feedback that discusses the correct answer as well as each of the wrong answers, and citations to relevant articles.

Estimated Time to Complete the Educational Activity

One hour for every 6 questions answered correctly.

Bibliography

Each clinical vignette includes citations and references.

Hardware/Software Requirements

Windows

  • Google Chrome 30+, Safari 5.0+, Internet Explorer 11.0+, Mozilla Firefox 10.0+, Microsoft Edge
    Recommended: Google Chrome 39+, Safari 7+, Internet Explorer 11, or Firefox 32+
  • Windows 7 (32-bit and 64-bit), Windows 8+. Windows 7+ is recommended.
  • Minimum 1 GB of RAM but 2 GB or greater is recommended
  • 2.33 GHz or faster x86-compatible processor, or Intel® Atom™ 1.6 GHz or faster processor for netbooks
  • Display resolution: 1024 × 768 or better

Mac OS

  • Google Chrome 14+, Safari 5.0+, Mozilla Firefox 12.0+
    Recommended: Google Chrome 39+, Safari 7+, or Firefox 32+
  • Mac OS X v10.6+
  • Minimum 1 GB of RAM but 2 GB or greater is recommended
  • Intel Core™ Duo 1.33GHz or faster processor
  • Display resolution: 1024 × 768 or better

Mobile/Tablet

NEJM Knowledge+ apps are available for iOS and Android smartphones and tablets; Android phones may access NEJM Knowledge+ through our mobile-optimized browser version.

  • iOS devices running OS 7+(includes iPhone and iPad devices). iOS version 8+ is recommended.
  • Android version 4+ (includes smartphones and tablets). Android version 5+ is recommended. Note: Android phones will also support the browser version of each product (Chrome recommended).

Contact Information

For all questions and comments, please contact NEJM Knowledge+ by email at knowledgeplussupport@nejm.org or call toll-free +1-855-318-9303 (within the USA and Canada) or +1-781-434-7998.

Policy on Privacy and Confidentiality

Read our Privacy Policy.

Copyright

Copyright information can be found in the NEJM Group Terms of Use.